The user is considering switching from finasteride and RU58841 to dutasteride due to ongoing hair loss concerns. They are unsure if the hair loss is due to shedding or worsening condition.
The user is seeking an alternative solvent for pyrilutamide due to skin irritation from ethanol and propylene glycol. They experienced similar issues with topical minoxidil.
A female user is considering using RU58841 with minoxidil 2.5% to reduce side effects like facial hair from minoxidil 5%, while also using copper peptides and a hair serum. Other users discuss alternative treatments like spironolactone, alfatradiol, and the side effects of finasteride.
A user shared an 8.5-month update on their hair transplant of 1064 grafts done by Dr. Kaan Pekiner in Ankara, Turkey, costing $3500. They are also using finasteride 2.25 mg weekly and have reduced shampoo use.
New hair loss treatments PP405 and VDPHL01 are discussed with skepticism and hope, alongside existing treatments like minoxidil and finasteride. Users express frustration over limited progress since the 1980s but remain cautiously optimistic.
The conversation is about a user obtaining a compounded treatment for hair loss, including 0.1% latanoprost, 0.2% melatonin, and 1% cetirizine. The user also uses 2.5 mg dutasteride, 5 mg minoxidil, and RU58841 daily, and is at Norwood 2.
PP405 is a new hair loss treatment that may outperform minoxidil and finasteride by growing thick hair in bald areas within four weeks. Its release is expected around 2028, but concerns about its long-term efficacy and cost remain.
The conversation discusses the effectiveness and safety of hair loss treatments, specifically RU58841 and Pyrilutimide (Pyril), with users sharing that Pyril was no more effective than a placebo and expressing concerns about the safety of RU58841 based on personal experiences and the lack of pharmaceutical interest.
The conversation is about using RU58841 powder for hair loss treatment and whether to mix it with ethanol/PG or Minoxidil. The user has been using Minoxidil for years with less efficacy and is considering the best method for combining treatments.
The conversation is about the availability of hair loss treatments Breezula, SM04554, Follica FOL-004, and Follicum FOL-005 in Canada after FDA approval, including potential delays, loopholes for obtaining them, and insurance coverage.
The conversation discusses using RU58841 with octopirox or essential oils for hair loss treatment. The user is seeking advice on which variation to try.
A user shared their 11-month experience using a 272 diode red light hat for hair loss, noting decent results despite inconsistent use and no medication. Another user suggested that real treatment like minoxidil or finasteride is necessary for long-term hair maintenance.
The conversation is about the anticipated release date of phase II results for a hair loss treatment called GT20029 and the cautious optimism surrounding it due to past disappointments with similar treatments. Users expect an update in the next few months.
The user is exploring hair loss treatments in China, currently using finasteride and minoxidil, and is concerned about seborrheic dermatitis. Clinics are recommending selenium sulfide, doxycycline, and mesotherapy ampoules like PT88/PT66 or SP88/SP66, but the user is unsure about their effectiveness.
The conversation is about the safety of Breezula compared to RU58841 for hair loss treatment. The user believes Breezula is safer but less effective than RU58841.
Triple Hair Inc. developed a new topical treatment, TH07, combining Finasteride, Latanoprost, and Minoxidil for androgenic alopecia. Users discussed its effectiveness compared to other treatments and shared their own product combinations.
Hair loss discussion focused on 2% Fluridil's peak efficacy at 3 months and 7% Fluridil group buy results, including shedding decrease, side effects, and regrowth.
The conversation is about using DIY deoxyribose topical and botox injections for hair loss. The user is experimenting with these treatments and believes the science is strong.
Hope Medicine's announcement of the HMI-115 Phase II clinical trial for androgenetic alopecia in China; other related trials have been conducted or are ongoing in different countries, including Australia, US, and Europe. There is speculation that the product may be accepted across borders without additional testing.
A satirical post humorously discusses a fictional hair regrowth drug called PP405, with users joking about its effectiveness and bizarre presentation. The conversation includes humorous reactions and references to the absurdity of the content.
Hope Medicine received a $28M investment for HMI-115, a monoclonal antibody in phase II trials for treating androgenetic alopecia. Some users are skeptical about its effectiveness, while others find the investment and trial results encouraging.
The user is using RU58841, Minoxidil, and weekly microneedling for hair loss, having stopped finasteride due to side effects like low libido and depression. They are considering dutasteride as an alternative but are cautious due to past experiences with DHT blockers.
The conversation is about the lack of updates on GT20029, a potential hair loss treatment, and the user considering using dutasteride or RU58841 instead of minoxidil/finasteride due to the long duration of the latter treatments.
A 17-year-old shared progress pictures after using RU58841 and Minoxidil for 2 months, showing significant hair regrowth. Another user commented on the impressive results achieved in a short time.
A user is excited about scheduling a hair transplant for July 1st, after 2 years of using Minoxidil, finasteride, and RU58841 with no regrowth. The transplant will cost €2500-€3000 for 1000-1200 grafts, and the user chose to have it done locally rather than traveling abroad to save money.